Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (12915)	1/1/1998 9:46:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

Henry, I think the issue of profitabilty from Atkins comments is that they expect a yearly profit in 1999. This doesn't preclude then from having a quarterly profit in the 4th quarter of this year. But a profit is a profit and boy do we need them from LGND. All my friends that I have put into LGND are getting a little nervous.

To: Henry Niman who wrote (12915)	1/1/1998 2:24:00 PM
From: Night Trader	Read Replies (3) \| Respond to of 32384

Henry, Zacks is pretty sparse on details - just the numbers usually. Here's what they emailed me: ESTIMATE REVISIONS: LGND: BEAR STEARNS made new estimate for quarter ending 12/98 of $0.03 on 12/31/97

To: Henry Niman who wrote (12915)	1/1/1998 4:24:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

>>There is also evidence showing decreading PSA levels when prostate cancer patients are treated, and of course new cases of prostate cancer is 10 times higher than KS (using LGND's fall of '96 cheat sheet).<< Henry, what is this "cheat sheet?" Is it available online? As far as profitability in 4Q 98, its hard to imagine. If everything goes very smoothly, Panretin may be on the market by that time, but would be unlikely to have enough sales to make a profit, unless they are expecting a large milestone payment or some such thing at that time.